ClinicaliQ Trial Snapshot
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer — Recruiting • Phase I • Oncology • NCT07567846.
- Investigational Agent: GDC-1261 is being tested for the first time in prostate cancer patients to assess its safety profile, how the body processes it (pharmacokinetics), and preliminary anti-tumour activity, whilst identifying optimal dosing for future trials.
- Patient Population: The trial includes adults with advanced or metastatic prostate cancer; specific eligibility criteria (performance status, organ function, prior treatments) would determine individual patient suitability.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Eligibility Snapshot
- : * Eastern Cooperative Oncology Group (ECOG) Performance Status of = 3 months * Histologically or cytologically confirmed prostate adenocarcinoma * Disease progression during or following the direct prior line of therapy * Ongoing androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonist or antagonist, or have had bilateral orchiectomy * Metastatic disease * Adequate end organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.